

AMENDMENT THIRTEEN
TO THE
SACRAMENTO INDEPENDENT HOTEL, RESTAURANT & TAVERN EMPLOYEES WELFARE
TRUST

WHEREAS, the Board of Trustees of the Sacramento Independent Hotel, Restaurant and Tavern Employees Welfare Plan (the "Plan") intends to amend the self-funded indemnity PPO Plan (with Aetna) to affirm the exclusion of coverage for gene therapy as it is considered an experimental and investigational medical expense, effective January 1, 2020; and

THEREFORE, the Board of Trustees amends the Plan as follows:


Amendment

The Board of Trustees of the Plan has amended Section C, "Indemnity Medical Plan Exclusions and Limitations" under Article IX, CLARIFICATION OF INDEMNITY PLAN BENEFITS on page 46 of the Summary Plan Description (also known as the Plan Document) by adding new item "67" as follows:

(67) Gene Therapy Exclusion. Effective January 1, 2020, the Plan clarifies that it does not cover nor has ever covered any medical and/or prescription drug charges for or related to Gene therapy, whether those therapies have received approval from the U.S. Food and Drug Administration (FDA), including future products as determined by the FDA, or are considered experimental or investigation, and related services. The following is not a comprehensive list of examples of gene therapy since new applications for gene therapies are submitted every year. Aetna will maintain a list of excluded products by reviewing the clinical policy bulletins and the FDA list for any changes.

Exondys 51 (eteplirsen)
Imlyglyc (talimogene laherparepvec)
Kymriah (tisagenlecleucel)
Luxturna (voretigene neparvovec-rzyl)
Spinraza (nusinersen)
Yescarta (axicabtagene ciloleucel)
Zolgensma (Onasemnogene abeparvovec-xioi).

Approved:

UNION TRUSTEES:


EMPLOYER TRUSTEES:


AMENDMENT THIRTEEN
TO THE
SACRAMENTO INDEPENDENT HOTEL, RESTAURANT & TAVERN EMPLOYEES WELFARE
TRUST

WHEREAS, the Board of Trustees of the Sacramento Independent Hotel, Restaurant and Tavern Employees Welfare Plan (the "Plan") intends to amend the self-funded indemnity PPO Plan (with Aetna) to affirm the exclusion of coverage for gene therapy as it is considered an experimental and investigational medical expense, effective January 1, 2020; and

THEREFORE, the Board of Trustees amends the Plan as follows:


Amendment


The Board of Trustees of the Plan has amended Section G. "Indemnity Medical Plan Exclusions and Limitations" under Article IX. CLARIFICATION OF INDMENITY PLAN BENEFITS on page 46 of the Summary Plan Description (also known as the Plan Document) by adding new item "67" as follows:

(67) Gene Therapy Exclusion. Effective January 1, 2020, the Plan clarifies that it does not cover nor has ever covered any medical and/or prescription drug charges for or related to Gene therapy, whether those therapies have received approval from the U.S. Food and Drug Administration (FDA), including future products as determined by the FDA, or are considered experimental or investigation, and related services. The following is not a comprehensive list of examples of gene therapy since new applications for gene therapies are submitted every year. Aetna will maintain a list of excluded products by reviewing the clinical policy bulletins and the FDA list for any changes.

Exondys 51 (eteplirsen)
Imlytic (talimogene laherparepvec)
Kymriah (tisagenlecleucel)
Luxturna (voretigene neparvovec-rzyl)
Spinraza (nusinersen)
Yescarta (axicabtagene ciloleucel)
Zolgensma (Onasemnogene abeparvovec-xioi).

Approved:

UNION TRUSTEES:

Regina George

EMPLOYER TRUSTEES:

Linda K. Pfeifer

B.R.

AMENDMENT THIRTEEN
TO THE
SACRAMENTO INDEPENDENT HOTEL, RESTAURANT & TAVERN EMPLOYEES WELFARE
TRUST

WHEREAS, the Board of Trustees of the Sacramento Independent Hotel, Restaurant and Tavern Employees Welfare Plan (the "Plan") intends to amend the self-funded indemnity PPO Plan (with Aetna) to affirm the exclusion of coverage for gene therapy as it is considered an experimental and investigational medical expense, effective January 1, 2020; and

THEREFORE, the Board of Trustees amends the Plan as follows:

Amendment


The Board of Trustees of the Plan has amended Section G, "Indemnity Medical Plan Exclusions and Limitations" under Article IX, CLARIFICATION OF INDMENITY PLAN BENEFITS on page 46 of the Summary Plan Description (also known as the Plan Document) by adding new item "67" as follows:

(67) Gene Therapy Exclusion. Effective January 1, 2020, the Plan clarifies that it does not cover nor has ever covered any medical and/or prescription drug charges for or related to Gene therapy, whether those therapies have received approval from the U.S. Food and Drug Administration (FDA), including future products as determined by the FDA, or are considered experimental or investigation, and related services. The following is not a comprehensive list of examples of gene therapy since new applications for gene therapies are submitted every year. Aetna will maintain a list of excluded products by reviewing the clinical policy bulletins and the FDA list for any changes.

Exondys 51 (eteplirsen)
Imlygic (talimogene laherparepvec)
Kymriah (tisagenlecleucel)
Luxturna (voretigene neparvovec-rzyl)
Spinraza (nusinersen)
Yescarta (axicabtagene ciloleucel)
Zolgensma (Onasemnogene abeparvovec-xioi).

Approved:

UNION TRUSTEES:



EMPLOYER TRUSTEES:
